{"id":"NCT01810783","sponsor":"H. Lundbeck A/S","briefTitle":"Brexpiprazole in Patients With Schizophrenia","officialTitle":"Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2013-03-14","resultsPosted":"2017-02-23","lastUpdate":"2017-03-27"},"enrollment":210,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"}],"summary":"To determine the safety and efficacy of brexpiprazole during long-term treatment.","primaryOutcome":{"measure":"Safety and Tolerability","timeFrame":"Up to 52 weeks and a safety follow-up by telephone contact or clinic visit after 30 days after the last dose of investigational medicinal product (IMP)","effectByArm":[{"arm":"Brexpiprazole","deltaMin":337,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":48,"countries":["United States","Estonia","Poland","Romania","Russia","Serbia","Slovakia","Ukraine"]},"refs":{"pmids":["35235720","34901863"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":209},"commonTop":["Weight increased","Headache","Insomnia"]}}